by Eric Christianson | Aug 20, 2025 | Clinical Guideline Updates For Pharmacists
The 2025 Hypertension guidelines are out! The alphabet soup of groups that contributed to the guidelines are as follows: AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM – I didn’t make that up! I made my way through the guidelines and wanted to...
by Eric Christianson | Feb 28, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
A new treatment for chronic weight management is likely on the way. In a recent trial, investigators looked at semaglutide for weight loss. The final results of the STEP1 trial (Semaglutide Treatment Effect in People with obesity) were recently reported in the New...
by Eric Christianson | Jan 3, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists, Polypharmacy Cases And The Prescribing Cascade
The GLP-1 Agonists have grown significantly in their popularity and there are good reasons for that increase in use. They promote weight loss which is a big problem in the majority of our type 2 diabetes patients. In addition to this benefit, they have also been shown...
by Eric Christianson | Nov 22, 2020 | Clinical Pharmacy News and New Drug Updates
Working with geriatric patients and providers in primary care, I definitely have to stay up to date with regards to diabetes therapy. There have been a couple of diabetes updates in 2020 that I wanted to make sure you were aware of. The SGLT2 inhibitors is a class of...
by Eric Christianson | Sep 16, 2020 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
GLP-1 agonists are an effective medication in treating type 2 diabetes mellitus. GLP-1 agonists are a synthetic version of the body’s naturally occurring GLP-1. However, synthetic GLP-1 has the advantage of being resistant to DPP4 degradation. GLP-1 agonists have...
